Science Explorer Back to mapMap
Discussion
Company · Sunnyvale · United States

Pharmacyclics (United States)

In research, Pharmacyclics (United States) stands highest in Health Sciences (#9,542 of 16,688 worldwide) and Medicine (#10,502 of 14,558 worldwide), over all time.

pharmacyclics.comROR OpenAlex
World rank, all time
#24,832
of 34,923
Rank in United States
#5,169
of 7,310
Research works
229
▼ 49% vs 2018-21
Citations
11k
46.7 per fractional work
Top-10% rate
16.9%
all institutions 10.0%
vs its own fields
1.08×
1.00× is exactly expected
Open access
22%
world 40%
International
16%
world 18%
Pharmacyclics (United States)

What is Pharmacyclics (United States) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Health SciencesDomain #9,542 of 16,688 25.2%124
MedicineField #10,502 of 14,558 25.4%123

Each strip is that field's whole ranked pool, with the notch where Pharmacyclics (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Pharmacyclics (United States) work in?

In all years, 54% of research at Pharmacyclics (United States) is in Health Sciences, 24% in Life Sciences. Its largest fields are Medicine (54%), Biochemistry, Genetics and Molecular Biology (18%), Engineering (10%). It does 2.3× the world's share of Health Sciences.

Health Sciences: 124 fractional works · 54.2% of its workMedicine: 123 fractional works · 53.7% of its workGenetics: 37 fractional works · 16.2% of its workPathology and Forensic Medicine: 18 fractional works · 7.7% of its workPulmonary and Respiratory Medicine: 18 fractional works · 7.7% of its workOncology: 17 fractional works · 7.4% of its workRadiology, Nuclear Medicine and Imaging: 11 fractional works · 4.9% of its workHematology: 9 fractional works · 3.9% of its workPublic Health, Environmental and Occupational Health: 3 fractional works · 1.2% of its workGastroenterology: 1 fractional works · 0.5% of its workEpidemiology: 1 fractional works · 0.4% of its workPharmacology: 1 fractional works · 0.4% of its workSurgery: 1 fractional works · 0.4% of its workNeurology: 1 fractional works · 0.3% of its workRheumatology: 1 fractional works · 0.3% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 0.3% of its workOphthalmology: 1 fractional works · 0.3% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 0.2% of its workDermatology: 0 fractional works · 0.2% of its workSmaller subfields together: 3 fractional works · 1.1% of its workNursing: 1 fractional works · 0.4% of its workNutrition and Dietetics: 1 fractional works · 0.4% of its workDentistry: 0 fractional works · 0.0% of its workHealth Professions: 0 fractional works · 0.0% of its workLife Sciences: 55 fractional works · 24.0% of its workBiochemistry, Genetics and Molecular Biology: 42 fractional works · 18.3% of its workMolecular Biology: 34 fractional works · 14.7% of its workCancer Research: 3 fractional works · 1.3% of its workCell Biology: 2 fractional works · 0.9% of its workBiophysics: 1 fractional works · 0.6% of its workBiotechnology: 1 fractional works · 0.3% of its workGenetics: 1 fractional works · 0.3% of its workPhysiology: 1 fractional works · 0.2% of its workImmunology and Microbiology: 8 fractional works · 3.6% of its workImmunology: 8 fractional works · 3.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 3 fractional works · 1.3% of its workToxicology: 1 fractional works · 0.6% of its workPharmaceutical Science: 1 fractional works · 0.4% of its workPharmacology: 1 fractional works · 0.3% of its workNeuroscience: 1 fractional works · 0.4% of its workCellular and Molecular Neuroscience: 1 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 0.3% of its workPhysical Sciences: 49 fractional works · 21.5% of its workEngineering: 23 fractional works · 10.2% of its workBiomedical Engineering: 11 fractional works · 4.7% of its workElectrical and Electronic Engineering: 10 fractional works · 4.4% of its workOcean Engineering: 1 fractional works · 0.4% of its workSafety, Risk, Reliability and Quality: 1 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 0.4% of its workMaterials Science: 11 fractional works · 5.0% of its workMaterials Chemistry: 10 fractional works · 4.4% of its workElectronic, Optical and Magnetic Materials: 1 fractional works · 0.3% of its workBiomaterials: 1 fractional works · 0.2% of its workChemistry: 8 fractional works · 3.7% of its workOrganic Chemistry: 5 fractional works · 2.3% of its workInorganic Chemistry: 2 fractional works · 0.7% of its workPhysical and Theoretical Chemistry: 1 fractional works · 0.4% of its workSpectroscopy: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workComputer Science: 3 fractional works · 1.5% of its workArtificial Intelligence: 1 fractional works · 0.6% of its workHardware and Architecture: 1 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.6% of its workPhysics and Astronomy: 2 fractional works · 0.8% of its workAtomic and Molecular Physics, and Optics: 2 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.1% of its workChemical Engineering: 0 fractional works · 0.1% of its workMathematics: 0 fractional works · 0.1% of its workEnvironmental Science: 0 fractional works · 0.1% of its workSocial Sciences: 1 fractional works · 0.3% of its workDecision Sciences: 0 fractional works · 0.1% of its workSocial Sciences: 0 fractional works · 0.1% of its workPsychology: 0 fractional works · 0.0% of its workALL ITS WORKPharmacyclics(United States)229fractional works, all years
Life Sciences24%Physical Sciences22%Health Sciences54%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 22 fields, with their numbers
    1. Medicine12353.7%
    2. Nursing10.4%
    3. Dentistry00.0%
    4. Health Professions00.0%
    1. Biochemistry, Genetics and Molecular Biology4218.3%
    2. Immunology and Microbiology83.6%
    3. Pharmacology, Toxicology and Pharmaceutics31.3%
    4. Neuroscience10.4%
    5. Agricultural and Biological Sciences10.3%
    1. Engineering2310.2%
    2. Materials Science115.0%
    3. Chemistry83.7%
    4. Computer Science31.5%
    5. Physics and Astronomy20.8%
    6. Chemical Engineering00.1%
    7. Mathematics00.1%
    8. Environmental Science00.1%
    1. Decision Sciences00.1%
    2. Social Sciences00.1%
    3. Psychology00.0%
    4. Economics, Econometrics and Finance00.0%
    5. Business, Management and Accounting00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.27× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 0.70× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 3.94× its world share, 0 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 4.31× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.83× its world share, 0 worksChemistryComputer Science: 1.00× its world share, 1 worksComputer ScienceEngineering: 0.52× its world share, 1 worksEngineeringMathematics: 1.11× its world share, 0 worksMathematicsHealth Professions: 0.06× its world share, 0 worksHealth ProfessionsMedicine: 3.56× its world share, 9 worksMedicineDecision Sciences: 2.69× its world share, 0 worksDecision Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 4.3×. Every wedge is a field page.

All 11 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics4.31×0 works
  2. Immunology and Microbiology3.94×0 works
  3. Medicine3.56×9 works
  4. Decision Sciences2.69×0 works
  5. Mathematics1.11×0 works
  6. Computer Science1.00×1 works
  7. Chemistry0.83×0 works
  8. Biochemistry, Genetics and Molecular Biology0.70×0 works
  9. Engineering0.52×1 works
  10. Agricultural and Biological Sciences0.27×0 works
  11. Health Professions0.06×0 works

Who are the top researchers at Pharmacyclics (United States)?

Ranked on the quality score, Betty Y Chang, Lee A. Honigberg and Danelle Frances James lead among researchers whose main affiliation is Pharmacyclics (United States).

  1. 1 Betty Y Chang United States · #36,683 worldwide 21k citations · 190 works
  2. 2 Lee A. Honigberg United States · #128,342 worldwide 7.1k citations · 69 works
  3. 3 Danelle Frances James United States · #161,597 worldwide 15k citations · 198 works
  4. 4 Fong Clow United States · #185,939 worldwide 13k citations · 48 works
  5. 5 Joseph J. Buggy United States · #194,119 worldwide 18k citations · 137 works
  6. 6 Mei L. Cheng United States · #345,245 worldwide 5.1k citations · 35 works
  7. 7 Lori Appel Styles United States · #385,075 worldwide 8.8k citations · 130 works
  8. 8 Markus Frederic Renschler United States · #562,284 worldwide 12k citations · 103 works
  9. 9 Tarak D. Mody United States · #639,552 worldwide 2.5k citations · 53 works
  10. 10 Juthamas Sukbuntherng United States · #731,872 worldwide 7.4k citations · 82 works
All ranked researchers at Pharmacyclics (United States)

What are the most cited papers from Pharmacyclics (United States)?

The most cited paper from Pharmacyclics (United States) is "Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia" (John C. Byrd et al., 2013), with 2,283 citations. Next come "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma" (1,710) and "Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia" (1,649).

Most cited papers
#PaperReleasedCitations
1 Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia John C. Byrd et al. · New England Journal of Medicine Open access 19 Jun 2013 2,283
2 Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang et al. · New England Journal of Medicine Open access 19 Jun 2013 1,710
3 Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd et al. · New England Journal of Medicine Open access 31 May 2014 1,649
4 Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger et al. · New England Journal of Medicine Open access 6 Dec 2015 1,604
5 The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Lee A. Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences Open access 6 Jul 2010 1,553
All 60 most cited papers, with filters and sorting

Which keywords describe research at Pharmacyclics (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Rituximab, Prognostic Factors, Therapeutic Targets, Chronic Lymphocytic Leukemia, Genomic Aberrations, PET Imaging, Reactive Oxygen Species and Lymphoma.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Rituximab52▲ 144×3 topics
  2. Prognostic Factors43▲ 41×10 topics
  3. Therapeutic Targets37▲ 68×4 topics
  4. Chronic Lymphocytic Leukemia35▲ 317×1 topic
  5. Genomic Aberrations35▲ 317×1 topic
  6. PET Imaging22▲ 45×4 topics
  7. Reactive Oxygen Species20▲ 17×7 topics
  8. Lymphoma19▲ 56×3 topics
  9. Nanoparticles18▲ 5.8×7 topics
  10. Classification17▲ 21×2 topics
  11. Genetic Pathogenesis17▲ 124×1 topic
  12. Molecular Profiling17▲ 63×1 topic
  13. Immunotherapy17▲ 11×12 topics
  14. Photodynamic Therapy16▲ 44×3 topics
  15. Cancer Therapy14▲ 9.8×9 topics
  16. Cancer Treatment13▲ 22×5 topics
  17. Antimicrobial10▲ 16×3 topics
  18. Clinical Applications10▲ 57×2 topics
  19. Photosensitizers10▲ 176×1 topic
  20. Singlet Oxygen10▲ 176×1 topic
  21. Metal Complexes10▲ 24×2 topics
  22. Chemotherapy8▲ 5.2×12 topics
  23. Glycosylation8▲ 16×3 topics
  24. Self-Assembly8▲ 8.7×4 topics
  25. Monoclonal Antibodies8▲ 24×3 topics
  26. Therapeutic Antibodies8▲ 26×2 topics
  27. Antibody Engineering8▲ 33×1 topic
  28. Fc Receptors8▲ 33×1 topic
  29. Gene Expression7▲ 5.0×6 topics
  30. Tumor Targeting7▲ 22×3 topics
  31. Targeted Therapy6▲ 13×4 topics
  32. Epigenetic Regulation6▲ 13×3 topics
  33. Fluorescence Imaging6▲ 24×1 topic
  34. Photothermal Therapy6▲ 32×1 topic
  35. Phthalocyanines6▲ 61×1 topic
  36. Porphyrins6▲ 61×1 topic
  37. Anticancer Agents6▲ 11×7 topics
  38. Mutation6▲ 16×3 topics
  39. Transcriptional Regulation6▲ 10×4 topics
  40. HDAC Inhibitors6▲ 128×1 topic

Which research topics does Pharmacyclics (United States) publish most on?

By volume in 2022-now: Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Reliability and Maintenance Optimization and Cancer Immunotherapy and Biomarkers.

Chronic Lymphocytic Leuk…3Chronic Lymphocytic Leukemia Research: 3 fractional worksLymphoma Diagnosis and T…2Lymphoma Diagnosis and Treatment: 2 fractional worksReliability and Maintenance Optimization: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksIntelligent Tutoring Systems and Adaptive Learning: 0 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksRadiopharmaceutical Chemistry and Applications: 0 fractional worksHER2/EGFR in Cancer Research: 0 fractional worksChronic Myeloid Leukemia Treatments: 0 fractional worksNanoplatforms for cancer theranostics: 0 fractional works
GeneticsPathology and Forensic MedicineSafety, Risk, Reliability and QualityOncology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Chronic Lymphocytic Leukemia Research Genetics 3 works
  2. 2 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 2 works
  3. 3 Reliability and Maintenance Optimization Safety, Risk, Reliability and Quality 0 works
  4. 4 Cancer Immunotherapy and Biomarkers Oncology 0 works
  5. 5 Intelligent Tutoring Systems and Adaptive Learning Artificial Intelligence 0 works
  6. 6 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  7. 7 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
  8. 8 HER2/EGFR in Cancer Research Oncology 0 works
  9. 9 Chronic Myeloid Leukemia Treatments Hematology 0 works
  10. 10 Nanoplatforms for cancer theranostics Biomedical Engineering 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available21.7%not open78.3%

World: 40% of research is openly available.

with international co-authors16.2%domestic only83.8%

World: 18% is written across borders.

How has Pharmacyclics (United States)'s research output changed?

Output in 2022-2025 was 49% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Pharmacyclics (United States) as a percentage of every work published that year, 0.000014% in 2024.

still counting0.00050%0.0010%Pharmacyclics (United States)0.000026% in 202519801990200020102020

Fractional works of Pharmacyclics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Sunnyvale

All research institutions in Sunnyvale

Share Pharmacyclics (United States)'s ranking

Pharmacyclics (United States) on Science Explorer

A card with Pharmacyclics (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Pharmacyclics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.